We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer
Read MoreHide Full Article
Key Takeaways
Revolution Medicines wins EU approval for Rasonque in previously treated metastatic pancreatic cancer.
Rasonque cut the risk of death by 60% and nearly doubled median overall survival versus chemotherapy.
Rasonque generated $197.6 million in U.S. revenue in five weeks, with European expansion ahead.
Revolution Medicines (RVMD - Free Report) announced that the European Commission (EC) has approved its once-daily oral pill Rasonque (daraxonrasib) for adults with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received at least one prior systemic therapy. The approval covers patients with or without an identified RAS tumor mutation.
The approval was expected after the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) issued a positive opinion recommending the drug’s approval last month. Rasonque was approved for a similar indication by the FDA in August 2026.
Both the EC and FDA decisions are supported by data from the phase III RASolute 302 study, which showed that the oral pill reduced the risk of death by 60% compared with cytotoxic chemotherapy and nearly doubled median overall survival. The treatment also significantly improved progression-free survival and quality-of-life measures.
So far, the commercial performance of Rasonque has been encouraging. Despite the U.S. launch in late August, the company generated $197.6 million in net product revenues from the drug in third-quarter 2026, reflecting approximately five weeks of commercial availability. More than 5,000 unique patients received the drug during this period. However, the company noted that initial revenues also reflected channel inventory stocking and early-launch patient dynamics and may not be indicative of the drug's longer-term sales trajectory.
The EC approval should expand Rasonque's commercial opportunity in Europe, although uptake is likely to build gradually as access depends on country-specific pricing, health technology assessments and reimbursement processes. Revolution Medicines is working with the relevant assessment and reimbursement bodies across the region to support broader and timely patient access.
RVMD Stock’s Price Performance
Year to date, the company’s shares have surged nearly 110% compared with the industry’s 8% growth.
Image Source: Zacks Investment Research
More on Revolution Medicines’ Rasonque
The approval strengthens Revolution Medicines’ position in RAS-driven cancers and provides a commercial foundation for advancing its broader oncology pipeline. Rasonque is designed to target a broad spectrum of RAS-driven cancers, including PDAC, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
Beyond the currently approved indication, Revolution Medicines is evaluating the drug inseveral other PDAC settings in late-stage studies. While the RASolute 303 study is assessing the drug for the first-line metastatic setting of the disease, the RASolute 304 study is evaluating its efficacy as an adjuvant therapy for patients with resectable PDAC.
The company is also conducting the phase III RASolve 301 study, which is evaluating Rasonque in patients with locally advanced or metastatic RAS-mutated NSCLC. The initial data readout from this study is expected next year.
Revolution Medicines is also developing mutant-selective inhibitors, such as elironrasib (targets RAS G12C) and zoldonrasib (targets RAS G12D), that are designed to suppress the growth of specific RAS-bearing cancer cells. While both drugs are being evaluated in separate late-stage studies for NSCLC, zoldonrasib is also advancing in a phase III study for CRC.
To further strengthen its position in RAS-driven cancers, Revolution Medicines has established multiple clinical collaborations to evaluate its RAS inhibitors in combination regimens. These partnerships include collaborations with Bristol Myers (BMY - Free Report) , Summit Therapeutics (SMMT - Free Report) and Tango Therapeutics (TNGX - Free Report) .
Image: Bigstock
Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer
Key Takeaways
Revolution Medicines (RVMD - Free Report) announced that the European Commission (EC) has approved its once-daily oral pill Rasonque (daraxonrasib) for adults with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received at least one prior systemic therapy. The approval covers patients with or without an identified RAS tumor mutation.
The approval was expected after the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) issued a positive opinion recommending the drug’s approval last month. Rasonque was approved for a similar indication by the FDA in August 2026.
Both the EC and FDA decisions are supported by data from the phase III RASolute 302 study, which showed that the oral pill reduced the risk of death by 60% compared with cytotoxic chemotherapy and nearly doubled median overall survival. The treatment also significantly improved progression-free survival and quality-of-life measures.
So far, the commercial performance of Rasonque has been encouraging. Despite the U.S. launch in late August, the company generated $197.6 million in net product revenues from the drug in third-quarter 2026, reflecting approximately five weeks of commercial availability. More than 5,000 unique patients received the drug during this period. However, the company noted that initial revenues also reflected channel inventory stocking and early-launch patient dynamics and may not be indicative of the drug's longer-term sales trajectory.
The EC approval should expand Rasonque's commercial opportunity in Europe, although uptake is likely to build gradually as access depends on country-specific pricing, health technology assessments and reimbursement processes. Revolution Medicines is working with the relevant assessment and reimbursement bodies across the region to support broader and timely patient access.
RVMD Stock’s Price Performance
Year to date, the company’s shares have surged nearly 110% compared with the industry’s 8% growth.
Image Source: Zacks Investment Research
More on Revolution Medicines’ Rasonque
The approval strengthens Revolution Medicines’ position in RAS-driven cancers and provides a commercial foundation for advancing its broader oncology pipeline. Rasonque is designed to target a broad spectrum of RAS-driven cancers, including PDAC, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
Beyond the currently approved indication, Revolution Medicines is evaluating the drug inseveral other PDAC settings in late-stage studies. While the RASolute 303 study is assessing the drug for the first-line metastatic setting of the disease, the RASolute 304 study is evaluating its efficacy as an adjuvant therapy for patients with resectable PDAC.
The company is also conducting the phase III RASolve 301 study, which is evaluating Rasonque in patients with locally advanced or metastatic RAS-mutated NSCLC. The initial data readout from this study is expected next year.
Revolution Medicines is also developing mutant-selective inhibitors, such as elironrasib (targets RAS G12C) and zoldonrasib (targets RAS G12D), that are designed to suppress the growth of specific RAS-bearing cancer cells. While both drugs are being evaluated in separate late-stage studies for NSCLC, zoldonrasib is also advancing in a phase III study for CRC.
To further strengthen its position in RAS-driven cancers, Revolution Medicines has established multiple clinical collaborations to evaluate its RAS inhibitors in combination regimens. These partnerships include collaborations with Bristol Myers (BMY - Free Report) , Summit Therapeutics (SMMT - Free Report) and Tango Therapeutics (TNGX - Free Report) .
Revolution Medicines, Inc. Price
Revolution Medicines, Inc. price | Revolution Medicines, Inc. Quote
RVMD’s Zacks Rank
Revolution Medicines currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.